Current Issue June 2012, Vol. 12, No. 3

Issue Highlights

Commentary

Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial
June 2012(Vol. 12 | No. 3 | Pages 151-154)
Nicolas Mounier, Natacha Heutte, Catherine Thieblemont, Josette Briere, Philippe Gaulard, Pierre Feugier, Hervé Ghesquieres, Eric Van Den Neste, Daniela Robu, Herve Tilly, Reda Bouabdallah, Violaine Safar, Bertrand Coiffier, Groupe d'Etude des Lymphomes de l'Adulte (GELA)
- Full Text
- PDF (235 KB)

Reviews

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target
June 2012(Vol. 12 | No. 3 | Pages 155-163)
Hong Liu, Samantha Tamashiro, Stavroula Baritaki, Manuel Penichet, Youhua Yu, Haiming Chen, James Berenson, Benjamin Bonavida

Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
June 2012(Vol. 12 | No. 3 | Pages 164-179)
Rodrigo Lopes da Silva

Changes Associated With Lenalidomide Treatment in the Gene Expression Profiles of Patients With Del(5q)
21 May 2012
Monika Belickova, Jaroslav Cermak, Michaela Dostalova Merkerova, Jitka Vesela, Zdenek Krejcik, Eliska Cechova, Zuzana Zemanova, Kyra Michalova, Hana Votavova, Miroslav Caniga, Radana Neuwirtova, Anna Jonasova
Micro-Abstract: We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14+ monocytes from 6 patients with del(5q). Our data demonstrate that ch...
Clinical Cytogenetics in Pediatric Acute Leukemia: An Update
21 May 2012
Maria Braoudaki, Fotini Tzortzatou-Stathopoulou
Abstract: Pediatric acute leukemias are generally characterized by recurrent numerical and structural chromosomal abnormalities, which are thought to be specifically associated with diagnosis and prog...
A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
14 May 2012
Yiming Chen, Hagop Kantarjian, Zeev Estrov, Stefan Faderl, Farhad Ravandi, Kristy Rey, Jorge Cortes, Gautam Borthakur
Micro-Abstract: This phase II study assessed the efficacy and safety of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (N = 18) and high-risk myelodysplastic syndrome (N = 9)...
Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia
07 May 2012
Teodora Karan-Djurasevic, Vuk Palibrk, Tatjana Kostic, Vesna Spasovski, Gordana Nikcevic, Sanja Srzentic, Milica Colovic, Natasa Colovic, Ana Vidovic, Darko Antic, Biljana Mihaljevic, Sonja Pavlovic, Natasa Tosic
Micro-Abstract: The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We foun...
Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms
27 April 2012
Jonathan R. Fromm, Julie A. McEarchern, Dana Kennedy, Anju Thomas, Andrei R. Shustov, Ajay K. Gopal
- Full Text
- PDF (1239 KB)

View More Articles in Press...

On the Cover

Editor-in-Chief:
Sundar Jagannath, MD

New Issue Alert

Free Trial Issue

Companion Journals

Attention Qualified Recipients

If you are a qualified recipient of the US print edition of Clinical Lymphoma, Myeloma & Leukemia, click here to access the online edition.

Access this journal onSciVerse ScienceDirect

About Clinical Lymphoma, Myeloma & Leukemia

Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Clinical Lymphoma, Myeloma & Leukemia is indexed by PubMed.

Clinical Lymphoma, Myeloma & Leukemia Access

Full-text articles are available from 2000 to the present. Access to abstracts is complimentary. Access to full text is limited to personal subscribers.

Activate Online Access

Journal Ranking

Publishing Information

Clinical Lymphoma Myeloma & Leukemia is published by Elsevier.